Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Metagenomi, Inc. Common Stock (MGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: MGX (1-star) is a SELL. SELL since 3 days. Simulated Profits (1.83%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10
1 Year Target Price $10
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.53% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.07M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.23 - 4.92 | Updated Date 11/10/2025 |
52 Weeks Range 1.23 - 4.92 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.33 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.8 | Actual - |
Profitability
Profit Margin -257.99% | Operating Margin (TTM) -246.53% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -37.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -68545492 | Price to Sales(TTM) 2.4 |
Enterprise Value -68545492 | Price to Sales(TTM) 2.4 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37533136 | Shares Floating 25276690 |
Shares Outstanding 37533136 | Shares Floating 25276690 | ||
Percent Insiders 28.09 | Percent Institutions 19.28 |
Upturn AI SWOT
Metagenomi, Inc. Common Stock
Company Overview
History and Background
Metagenomi, Inc. was founded in 2018 and focuses on developing next-generation gene editing tools using novel enzymes discovered from uncultivated environmental microbes. The company aims to address a wide range of genetic diseases.
Core Business Areas
- Gene Editing Platform: Development of a CRISPR-associated transposase (CAST) system for targeted integration of large DNA sequences into the genome.
- Therapeutic Development: Applying their gene editing platform to develop therapies for various genetic diseases, including liver, lung, and central nervous system disorders.
- Partnerships and Licensing: Collaborating with pharmaceutical companies to accelerate the development and commercialization of gene editing therapies.
Leadership and Structure
Brian C. Thomas is the CEO of Metagenomi. The company has a scientific advisory board and a management team with expertise in gene editing, drug development, and business development. The organizational structure includes research, development, and business operations departments.
Top Products and Market Share
Key Offerings
- CRISPR-associated Transposases (CASTs): A novel gene editing platform for large DNA sequence insertion. Market share is nascent as it's an early-stage technology. Competitors include companies working on CRISPR-Cas systems and other gene editing modalities like base editing and prime editing. Revenue is primarily from licensing agreements and collaborations.
- Gene Therapy Programs: Preclinical gene therapy programs targeting specific genetic diseases. Market share is currently 0 as the programs are in development. Competitors vary depending on the target disease, including established gene therapy companies and other biotech firms pursuing similar targets. No revenue is yet generated.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR technology and its potential to treat a wide range of diseases. The industry is competitive, with many companies developing novel gene editing tools and therapies.
Positioning
Metagenomi is positioned as a leader in next-generation gene editing, focusing on large DNA sequence integration using novel enzymes. Their competitive advantage lies in their unique CAST platform and their access to a diverse library of environmental microbes.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to be in the tens of billions of dollars. Metagenomi is positioned to capture a significant share of this market with its innovative platform.
Upturn SWOT Analysis
Strengths
- Novel gene editing platform (CAST)
- Access to diverse microbial library
- Strong scientific team
- Strategic partnerships
Weaknesses
- Early stage of development
- Limited clinical data
- High cash burn rate
- Dependence on partnerships
Opportunities
- Expanding therapeutic applications
- Securing additional partnerships
- Advancing programs into clinical trials
- Potential for acquisitions
Threats
- Competition from other gene editing companies
- Regulatory hurdles
- Patent disputes
- Clinical trial failures
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
- BEAM
Competitive Landscape
Metagenomi's CAST platform offers potential advantages over existing CRISPR-Cas systems in terms of large DNA sequence integration. However, they are behind other companies in terms of clinical development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by R&D progress and collaborations, rather than revenue.
Future Projections: Future growth is projected to be driven by advancing therapeutic programs into clinical trials and securing additional partnerships. Analyst estimates are not yet widely available.
Recent Initiatives: Recent initiatives include IND filing for their lead program, expansion of their gene editing platform, and securing partnerships with pharmaceutical companies.
Summary
Metagenomi is an early-stage biotechnology company with a promising gene editing platform. The company's novel CAST technology and access to microbial diversity provides a competitive advantage. Key risks include clinical trial success, competition, and dependence on partnerships. The company's future hinges on proving the efficacy and safety of its platform in clinical trials and securing additional funding or strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Metagenomi, Inc. website
- SEC filings
- Industry reports
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Financial projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metagenomi, Inc. Common Stock
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2024-02-09 | Co-Founder, CEO & Chairman of the Board Dr. Brian Charles Thomas Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 171 | Website https://metagenomi.co |
Full time employees 171 | Website https://metagenomi.co | ||
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.